Abbott’s Absolute Pro Vascular Self-Expanding Stent System receives FDA approval for treatment of iliac artery disease


The US Food and Drug Administration (FDA) has approved the Absolute Pro Vascular Self-Expanding Stent System for the treatment of iliac artery disease. This approval is supported by the MOBILITY (Omnilink Elite or Absolute Pro Stent used in the iliac artery) study, which demonstrated that Absolute Pro is safe and effective, even in patients with complex disease. 

“Iliac artery disease greatly impacts patients’ overall quality of life,” said Tony S Das, director, Peripheral Vascular Interventions, Cardiology Section, Presbyterian Heart Institute, Dallas, Texas, USA, and co-principal investigator of the MOBILITY trial. “The goal of treatment is to open narrowed iliac arteries to restore blood flow to the legs, thereby alleviating pain and improving the patient’s ability to walk farther and enjoy a more active lifestyle. With Absolute Pro, US physicians now have an additional option that is proven safe and effective to treat many patients with this debilitating disease.”

Absolute Pro is a self-expanding nitinol stent system made of a flexible material designed to allow the stent to conform to challenging lesions. It incorporates advanced technologies for optimal stent visibility, with a delivery system that is designed to minimise friction during stent deployment and ensure precise stent placement at the lesion site.